

REFERENCES

- Adami, R., Pezzotta, M., Cadile, F., Cuniolo, B., Rovati, G., Canepari, M., & Bottai, D. (2024). Physiological Features of the Neural Stem Cells Obtained from an Animal Model of Spinal Muscular Atrophy and Their Response to Antioxidant Curcumin. *International Journal of Molecular Sciences*, 25(15). <https://doi.org/10.3390/ijms25158364>
- Anandaradje, A., Kalita, B., Coumar, M. S., & Selvarajan, S. (2024). Molecular docking of curcumin and curcuminoids as human Zn⁺ dependent histone deacetylase (HDAC) enzyme inhibitors. *In Silico Pharmacology*, 12(1). <https://doi.org/10.1007/s40203-024-00221-4>
- Bora-Tatar, G., & Erdem-Yurter, H. (2014). Investigations of curcumin and resveratrol on neurite outgrowth: Perspectives on spinal muscular atrophy. In *BioMed Research International* (Vol. 2014). Hindawi Publishing Corporation. <https://doi.org/10.1155/2014/709108>
- Brown, S. J., Kline, R. A., Synowsky, S. A., Shirran, S. L., Holt, I., Sillence, K. A., Claus, P., Wirth, B., Wishart, T. M., & Fuller, H. R. (2022). The Proteome Signatures of Fibroblasts from Patients with Severe, Intermediate and Mild Spinal Muscular Atrophy Show Limited Overlap. *Cells*, 11(17). <https://doi.org/10.3390/cells11172624>
- Burghes, A. H. M. (1997). INVITED EDITORIAL When Is a Deletion Not a Deletion? When It Is Converted. In *Am. J. Hum. Genet* (Vol. 61).
- Burr, P., & Reddivari, A. K. R. (2023). Spinal Muscle Atrophy. *StatPearls*.

- Carrel, T. L., McWhorter, M. L., Workman, E., Zhang, H., Wolstencroft, E. C., Lorson, C., Bassell, G. J., Burghes, A. H. M., & Beattie, C. E. (2006). Survival motor neuron function in motor axons is independent of functions required for small nuclear ribonucleoprotein biogenesis. *Journal of Neuroscience*, *26*(43), 11014–11022. <https://doi.org/10.1523/JNEUROSCI.1637-06.2006>
- Cole, G. M., Teter, B., & Frautschy, S. A. (n.d.). *NEUROPROTECTIVE EFFECTS OF CURCUMIN*.
- Corey, D. R. (2017). Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. *Nature Neuroscience*, *20*(4), 497–499. <https://doi.org/10.1038/nn.4508>
- Crisafulli, S., Boccanegra, B., Vitturi, G., Trifirò, G., & De Luca, A. (2023). Pharmacological Therapies of Spinal Muscular Atrophy: A Narrative Review of Preclinical, Clinical–Experimental, and Real-World Evidence. In *Brain Sciences* (Vol. 13, Issue 10). Multidisciplinary Digital Publishing Institute (MDPI). <https://doi.org/10.3390/brainsci13101446>
- D’Amico, A., Mercuri, E., Tiziano, F. D., & Bertini, E. (2011a). Spinal muscular atrophy. In *Orphanet Journal of Rare Diseases* (Vol. 6, Issue 1). <https://doi.org/10.1186/1750-1172-6-71>
- D’Amico, A., Mercuri, E., Tiziano, F. D., & Bertini, E. (2011b). Spinal muscular atrophy. In *Orphanet Journal of Rare Diseases* (Vol. 6, Issue 1). <https://doi.org/10.1186/1750-1172-6-71>
- Dulka, B. (2021, June 15). *Prevalence of Spinal Muscular Atrophy*. MySMAteam.

- Farrar, M. A., & Kiernan, M. C. (2015). The Genetics of Spinal Muscular Atrophy: Progress and Challenges. In *Neurotherapeutics* (Vol. 12, Issue 2, pp. 290–302). Springer New York LLC. <https://doi.org/10.1007/s13311-014-0314-x>
- Feng, D., Cheng, Y., Meng, Y., Zou, L., Huang, S., & Xie, J. (2015). Multiple effects of curcumin on promoting expression of the exon 7-containing SMN2 transcript. *Genes and Nutrition*, *10*(6). <https://doi.org/10.1007/s12263-015-0486-y>
- Hassan, F. U., Rehman, M. S. U., Khan, M. S., Ali, M. A., Javed, A., Nawaz, A., & Yang, C. (2019). Curcumin as an alternative epigenetic modulator: Mechanism of action and potential effects. *Frontiers in Genetics*, *10*(JUN). <https://doi.org/10.3389/fgene.2019.00514>
- Hastings, M. L., Berniac, J., Liu, Y. H., Abato, P., Jodelka, F. M., Barthel, L., Kumar, S., Dudley, C., Nelson, M., Larson, K., Edmonds, J., Bowser, T., Draper, M., Higgins, P., & Krainer, A. R. (2009). Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy. *Science Translational Medicine*, *1*(5). <https://doi.org/10.1126/scitranslmed.3000208>
- Hatcher, H., Planalp, R., Cho, J., Torti, F. M., & Torti, S. V. (2008). Curcumin: From ancient medicine to current clinical trials. In *Cellular and Molecular Life Sciences* (Vol. 65, Issue 11, pp. 1631–1652). <https://doi.org/10.1007/s00018-008-7452-4>
- Kaufmann, P., McDermott, M. P., Darras, B. T., Finkel, R. S., Sproule, D. M., Kang, P. B., Oskoui, M., Constantinescu, A., Gooch, C. L., Foley, A. R., Yang, M. L., Tawil, R., Chung, W. K., Martens, W. B., Montes, J., Battista, V.,

- O'Hagen, J., Dunaway, S., Flickinger, J., ... De Vivo, D. C. (2012). Prospective cohort study of spinal muscular atrophy types 2 and 3. *Neurology*, 79(18), 1889–1897. <https://doi.org/10.1212/WNL.0b013e318271f7e4>
- Khirani, S., Colella, M., Caldarelli, V., Aubertin, G., Boulé, M., Forin, V., Ramirez, A., & Fauroux, B. (2013). Longitudinal course of lung function and respiratory muscle strength in spinal muscular atrophy type 2 and 3. *European Journal of Paediatric Neurology*, 17(6), 552–560. <https://doi.org/10.1016/j.ejpn.2013.04.004>
- Kolb, S. J., & Kissel, J. T. (2011). Spinal muscular atrophy: A timely review. In *Archives of Neurology* (Vol. 68, Issue 8, pp. 979–984). <https://doi.org/10.1001/archneurol.2011.74>
- Lefebvre, S., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., Denis Le Paslier, Il, Fr, J., Cohen, D., Weissenbach, J., Munnich, A., & Melki, J. (1995). Identification and Characterization of a Spinal Muscular Atrophy-Determining Gene. In *Cell* (Vol. 80).
- Lorson, C. L., Rindt, H., & Shababi, M. (2010). Spinal muscular atrophy: Mechanisms and therapeutic strategies. *Human Molecular Genetics*, 19(R1). <https://doi.org/10.1093/hmg/ddq147>
- Mailman, M. D., Heinz, J. W., Papp, A. C., Snyder, P. J., Sedra, M. S., Wirth, B., Burghes, A. H. M., & Prior, T. W. (2002). Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. *Genetics in Medicine*, 4(1), 20–26. <https://doi.org/10.1097/00125817-200201000-00004>

Markowitz, J. A., Singh, P., & Darras, B. T. (2012). Spinal muscular atrophy: A clinical and research update. In *Pediatric Neurology* (Vol. 46, Issue 1, pp. 1–12). <https://doi.org/10.1016/j.pediatrneurol.2011.09.001>

Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., Kissel, J. T., Nagendran, S., L'Italien, J., Sproule, D. M., Wells, C., Cardenas, J. A., Heitzer, M. D., Kaspar, A., Corcoran, S., ... Kaspar, B. K. (2017). Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. *New England Journal of Medicine*, 377(18), 1713–1722. <https://doi.org/10.1056/nejmoa1706198>

Messina, S., & Sframeli, M. (2020). New treatments in spinal muscular atrophy: Positive results and new challenges. *Journal of Clinical Medicine*, 9(7), 1–16. <https://doi.org/10.3390/jcm9072222>

Mohseni, J., Zabidi-Hussin, Z. A. M. H., & Sasongko, T. H. (2013). *Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy*. www.sbg.org.br

Namwan, N., Senawong, G., Phaosiri, C., Kumboonma, P., Somsakeesit, L. O., Samankul, A., Leerat, C., & Senawong, T. (2022a). HDAC Inhibitory and Anti-Cancer Activities of Curcumin and Curcumin Derivative CU17 against Human Lung Cancer A549 Cells. *Molecules*, 27(13). <https://doi.org/10.3390/molecules27134014>

Namwan, N., Senawong, G., Phaosiri, C., Kumboonma, P., Somsakeesit, L. O., Samankul, A., Leerat, C., & Senawong, T. (2022b). HDAC Inhibitory and Anti-Cancer Activities of Curcumin and Curcumin Derivative CU17 against

Human Lung Cancer A549 Cells. *Molecules*, 27(13).

<https://doi.org/10.3390/molecules27134014>

Novitasari, D., Nakamae, I., Istighfari Jenie, R., Yoneda-Kato, N., Kato, J. ya, & Meiyanto, E. (2024). Pentagamavunone-1 inhibits aggressive breast cancer cell proliferation through mitotic catastrophe and ROS-mediated activities: in vitro and in vivo studies. *Saudi Pharmaceutical Journal*, 32(1).

<https://doi.org/10.1016/j.jsps.2023.101892>

Patrizi, A. L., Tiziano, F., Zappata, S., Donati, M. A., Neri, G., & Brahe, C. (1999). *SMN protein analysis in fibroblast, amniocyte and CVS cultures from spinal muscular atrophy patients and its relevance for diagnosis.*

<http://www.stockton-press.co.uk/ejhg>

Peng, Y., Ao, M., Dong, B., Jiang, Y., Yu, L., Chen, Z., Hu, C., & Xu, R. (2021).

Anti-inflammatory effects of curcumin in the inflammatory diseases: Status, limitations and countermeasures. In *Drug Design, Development and Therapy* (Vol. 15, pp. 4503–4525). Dove Medical Press Ltd.

<https://doi.org/10.2147/DDDT.S327378>

Porter, N. J., & Christianson, D. W. (2019). Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases. In *Current Opinion in Structural Biology*

(Vol. 59, pp. 9–18). Elsevier Ltd.

<https://doi.org/10.1016/j.sbi.2019.01.004>

Prior, T. W., Krainer, A. R., Hua, Y., Swoboda, K. J., Snyder, P. C., Bridgeman, S.

J., Burghes, A. H. M., & Kissel, J. T. (2009). A Positive Modifier of Spinal

Muscular Atrophy in the SMN2 Gene. *American Journal of Human Genetics*, 85(3), 408–413. <https://doi.org/10.1016/j.ajhg.2009.08.002>

Prior, T. W., Leach, M. E., Finanger, E. ; L., Adam, M. P., Feldman, J., & Mirzaa, G. M. (2000). *Spinal Muscular Atrophy*.

Russman, B. S. (2007). Spinal muscular atrophy: Clinical classification and disease heterogeneity. *Journal of Child Neurology*, 22(8), 946–951. <https://doi.org/10.1177/0883073807305673>

Sakla, M. S., & Lorson, C. L. (2008). Induction of full-length survival motor neuron by polyphenol botanical compounds. *Human Genetics*, 122(6), 635–643. <https://doi.org/10.1007/s00439-007-0441-0>

Service Line: CADTH Common Drug Review Version: Final (with redactions)
CADTH Common Drug Review Clinical Review Report. (2021).

Spinraza, N. (. (2018). *CADTH COMMON DRUG REVIEW Clinical Review Report*
Indication: Treatment of patients with 5q SMA.

Stohs, S. J., Chen, O., Ray, S. D., Ji, J., Bucci, L. R., & Preuss, H. G. (2020). Highly bioavailable forms of curcumin and promising avenues for curcumin-based research and application: A review. In *Molecules* (Vol. 25, Issue 6). MDPI AG. <https://doi.org/10.3390/molecules25061397>

Surh, Y.-J., Chun, K.-S., Cha, H.-H., Han, S. S., Keum, Y.-S., Park, K.-K., & Lee, S. S. (2001). Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-κB activation. *Mutation Research/Fundamental*

and Molecular Mechanisms of Mutagenesis, 480–481, 243–268.

[https://doi.org/10.1016/S0027-5107\(01\)00183-X](https://doi.org/10.1016/S0027-5107(01)00183-X)

Tomeh, M. A., Hadianamrei, R., & Zhao, X. (2019). A review of curcumin and its derivatives as anticancer agents. In *International Journal of Molecular Sciences* (Vol. 20, Issue 5). MDPI AG. <https://doi.org/10.3390/ijms20051033>

Ucche, S., Murwanti, R., Ritmaleni, & Hayakawa, Y. (2020). *Anti-Metastatic Effects of Curcumin Analogues in a Mouse Breast Cancer Model*.

Utomo, R. Y., Wulandari, F., Novitasari, D., Lestari, B., Susidarti, R. A., Jenie, R. I., Kato, J. Y., Sardjiman, S., & Meiyanto, E. (2022). Preparation and Cytotoxic Evaluation of PGV-1 Derivative, CCA-1.1, as a New Curcumin Analog with Improved-Physicochemical and Pharmacological Properties. *Advanced Pharmaceutical Bulletin*, 12(3), 603–612. <https://doi.org/10.34172/apb.2022.063>

Wadman, R. I., Stam, M., Gijzen, M., Lemmink, H. H., Snoeck, I. N., Wijngaarde, C. A., Braun, K. P. J., Schoenmakers, M. A. G. C., van den Berg, L. H., Dooijes, D., & van der Pol, W.-L. (2017). Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0–4. *Journal of Neurology, Neurosurgery & Psychiatry*, 88(4), 365–367. <https://doi.org/10.1136/jnnp-2016-314292>

Zheleznyakova, G. Y., Kiselev, A. V., Vakharlovsky, V. G., Rask-Andersen, M., Chavan, R., Egorova, A. A., Schiöth, H. B., & Baranov, V. S. (2011). Genetic and expression studies of SMN2 gene in Russian patients with spinal muscular

atrophy type II and III. *BMC Medical Genetics*, 12.

<https://doi.org/10.1186/1471-2350-12-96>